ArticleInfection and immunity1999
Induction of cytokines and chemokines in human monocytes by Mycoplasma fermentans-derived lipoprotein MALP-2.
Article in Infection and immunity, 1999. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 37 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
37 citing papers in PubMed, 88 citations in OpenAlex.
- Intratumoural injection of the toll-like receptor-2/6 agonist 'macrophage-activating lipopeptide-2' in patients with pancreatic carcinoma: a phase I/II trial.British journal of cancer · 2007Trial
- Mycoplasma Contamination Alters the Expression Profile of Pro-Inflammatory Cytokines by Human Innate Immune Cells.Cell biochemistry and function · 2026Article
- Exploring the Mechanisms Underlying Cellular Uptake and Activation of Dendritic Cells by the GK-1 Peptide.ACS omega · 2024Article
- Pushing the envelope: Immune mechanism and application landscape of macrophage-activating lipopeptide-2.Frontiers in immunology · 2023Review
- Effects of Receptor Specificity and Conformational Stability of Influenza A Virus Hemagglutinin on Infection and Activation of Different Cell Types in Human PBMCs.Frontiers in immunology · 2022Article
- SARS-CoV-2, Zika viruses and mycoplasma: Structure, pathogenesis and some treatment options in these emerging viral and bacterial infectious diseases.Biochimica et biophysica acta. Molecular basis of disease · 2021Article
- A positive feedback loop reinforces the allergic immune response in human peanut allergy.The Journal of experimental medicine · 2021Article
- Targeting Toll-Like Receptor 2: Polarization of Porcine Macrophages by a Mycoplasma-Derived Pam2cys Lipopeptide.Vaccines · 2021Article
- Mycoplasmas-Host Interaction: Mechanisms of Inflammation and Association with Cellular Transformation.Microorganisms · 2020Review
- Effects of Mycoplasmas on the Host Cell Signaling Pathways.Pathogens (Basel, Switzerland) · 2020Review
- TLR Agonists as Mediators of Trained Immunity: Mechanistic Insight and Immunotherapeutic Potential to Combat Infection.Frontiers in immunology · 2020Review
- In vivo cancer vaccination: Which dendritic cells to target and how?Cancer treatment reviews · 2018Review
- The Role of Lipoproteins in Mycoplasma-Mediated Immunomodulation.Frontiers in microbiology · 2018Article
- The TLR-2/TLR-6 agonist macrophage-activating lipopeptide-2 augments human NK cell cytotoxicity when PGE2 production by monocytes is inhibited by a COX-2 blocker.Cancer immunology, immunotherapy : CII · 2015Article
- Sulfur compounds block MCP-1 production by Mycoplasma fermentans-infected macrophages through NF-κB inhibition.Journal of translational medicine · 2014Article
- Binding of CD14 to Mycoplasma genitalium-derived lipid-associated membrane proteins upregulates TNF-α.Inflammation · 2014Article
- Macrophage-activating lipopeptide-2 requires Mal and PI3K for efficient induction of heme oxygenase-1.PloS one · 2014Article
- TLR Agonists as Modulators of the Innate Immune Response and Their Potential as Agents Against Infectious Disease.Frontiers in immunology · 2014Review
- Mycoplasma fermentans MALP-2 induces heme oxygenase-1 expression via mitogen-activated protein kinases and Nrf2 pathways to modulate cyclooxygenase 2 expression in human monocytes.Clinical and vaccine immunology : CVI · 2013Article
- MALP-2 pre-treatment modulates systemic inflammation in hemorrhagic shock.Journal of inflammation (London, England) · 2013Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
4 authors at 3 institutions in 2 countries.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Bacterial infections are characterized by strong inflammatory reactions. The responsible mediators are often bacterially derived cell wall molecules, such as lipopolysaccharide or lipoteichoic acids, which typically stimulate monocytes and macrophages to release a wide variety of inflammatory cytokines and chemokines. Mycoplasmas, which lack a cell wall, may also stimulate monocytes very efficiently. This study was performed to identify mycoplasma-induced mediators. We investigated the induction of cytokines and chemokines in human monocytes exposed to the Mycoplasma fermentans-derived membrane component MALP-2 (macrophage-activating lipopeptide 2) by dose response and kinetic analysis. We found a rapid and strong MALP-2-inducible chemokine and cytokine gene expression which was followed by the release of chemokines and cytokines with peak levels after 12 to 20 h. MALP-2 induced the neutrophil-attracting CXC chemokines interleukin-8 (IL-8) and GRO-alpha as well as the mononuclear leukocyte-attracting CC chemokines MCP-1, MIP-1alpha, and MIP-1beta. Production of the proinflammatory cytokines tumor necrosis factor alpha and IL-6 started at the same time as chemokine release but required 10- to 100-fold-higher MALP-2 doses. The data show that the mycoplasma-derived lipopeptide MALP-2 represents a potent inducer of chemokines and cytokines which may, by the attraction and activation of neutrophils and mononuclear leukocytes, significantly contribute to the inflammatory response during mycoplasma infection.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.